Method development and validation for the estimation of gedatolisib in mouse plasma by tandem mass spectrometry and its application to pharmacokinetics studies
Authors:
- 10 April 2024
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 38 (7) , e5878
Abstract
A simple and a sensitive liquid chromatography–tandem mass spectrometry method was developed and validated for the quantification of gedatolisib in mouse plasma. The extraction technique involved a simple precipitation method to extract gedatolisib and idelalisib (internal standard) from mouse plasma. A clean chromatographic separation of gedatolisib and the internal standard was achieved on an Atlantis dC18 column using an isocratic mobile phase (10 mm ammonium formate and acetonitrile; 30:70% v/v, both supplemented with 0.1% formic acid) delivered at a flow rate of 0.7 ml/min. The total run time was 2.0 min, and gedatolisib and idelalisib were eluted at 0.80 and 0.95 min, respectively. Gedatolisib was monitored at m/z 616.40 → 488.20 and idelalisib at 416.05 → 176.10. All the required parameters for the method validation were performed as per US Food and Drug Administration guidelines, and the results were within the acceptance criteria. The method was accurate and proved to be precise at a linearity range of 1.33–2667 ng/ml. The accuracy for gedatolisib in mouse plasma was in the ranges 0.99–1.06% (intra‐day) and 0.96–1.04% (inter‐day). Gedatolisib appeared to be stable in a series of stability conditions. Gedatolisib showed a good intravenous profile when administered through a solution formulation.Keywords
This publication has 9 references indexed in Scilit:
- Design, Synthesis and Phenotypic Profiling of Simplified Gedatolisib AnaloguesPharmaceuticals, 2023
- The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settingsMolecular Oncology, 2021
- DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic StudyDrug Research, 2020
- Bioanalysis of Targeted Nanoparticles in Monkey Plasma via LC-MS/MSAnalytical Chemistry, 2019
- Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous InfusionClinical Pharmacology in Drug Development, 2018
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced CancerClinical Cancer Research, 2015
- A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).Journal of Clinical Oncology, 2014
- Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase InhibitorClinical Cancer Research, 2011
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitorsProceedings of the National Academy of Sciences, 2011